Belgium’s Cardio3, China’s Medisun Join Hands On Phase III Trials In U.S.
This article was originally published in PharmAsia News
Executive Summary
Belgium’s Cardio3 BioSciences secures 25 million euros from China’s Medisun International to aid clinical trial efforts in the United States on a heart failure treatment candidate.